CD274 and non-small cell lung carcinoma: By demonstrating the clinical benefits of pembrolizumab combined with chemotherapy over chemotherapy alone, KEYNOTE-189 and KEYNOTE-407 truly satisfied an unmet need for the PD-L1-low NSCLC population.